Pexeva is a drug owned by Sebela Ireland Ltd. It is protected by 2 US drug patents filed in 2013. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 04, 2025. Details of Pexeva's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7598271 | Crystalline paroxetine methane sulfonate |
May, 2025
(6 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5874447 | 4-Phenylpiperidine compounds for treating depression |
Jun, 2017
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Pexeva is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Pexeva's family patents as well as insights into ongoing legal events on those patents.
Pexeva's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Pexeva's generic launch date based on the expiry of its last outstanding patent is estimated to be May 04, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pexeva Generic API suppliers:
Paroxetine Mesylate is the generic name for the brand Pexeva. 2 different companies have already filed for the generic of Pexeva, with Actavis Labs Fl Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Pexeva's generic
Alternative Brands for Pexeva
Pexeva which is used for treating depression and obsessive-compulsive disorder., has several other brand drugs in the same treatment category and using the same active ingredient (Paroxetine Mesylate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Apotex |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Paroxetine Mesylate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Sebela Ireland Ltd |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Paroxetine Mesylate, Pexeva's active ingredient. Check the complete list of approved generic manufacturers for Pexeva
About Pexeva
Pexeva is a drug owned by Sebela Ireland Ltd. It is used for treating depression and obsessive-compulsive disorder. Pexeva uses Paroxetine Mesylate as an active ingredient. Pexeva was launched by Sebela Ireland Ltd in 2003.
Approval Date:
Pexeva was approved by FDA for market use on 03 July, 2003.
Active Ingredient:
Pexeva uses Paroxetine Mesylate as the active ingredient. Check out other Drugs and Companies using Paroxetine Mesylate ingredient
Treatment:
Pexeva is used for treating depression and obsessive-compulsive disorder.
Dosage:
Pexeva is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MG BASE | TABLET | Discontinued | ORAL |
| EQ 30MG BASE | TABLET | Discontinued | ORAL |
| EQ 20MG BASE | TABLET | Discontinued | ORAL |
| EQ 10MG BASE | TABLET | Discontinued | ORAL |